KY02111

Name: KY02111
Brand: DC Chemicals
SKU: DC1032
Price: 300.0 USD

Pack size & price

USD

Ready-made solution

Total$300

We match the best price and quality on market.

Product overview

Description & Application

KY02111 is a small molecule for cardiomyocyte differentiation research in human pluripotent stem cells.

Parameter	Value
Chemical Name	N-(6-Chlorobenzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide
CAS No.	1118807-13-8
Synonyms	KY02111; KY0211; N-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide; N-(6-Chlorobenzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide; 2-(3-(3,4-dimethoxyphenyl)propanamido)-6-chlorobenzothiazole; KY-02111; QC-8207; N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxy-benzenepropanamide; KY 02111; C18H17ClN2O3S; N-(6-Chloro-benzothiazol-2-yl)-3-(3,4-dimethoxy-phenyl)-propionamide; SYN5079; AOB3874; HMS3653K03; N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide; BCP07010; AM81229
Formula	C18H17ClN2O3S
M.Wt	376.8572
SMILES	ClC1C([H])=C([H])C2=C(C=1[H])SC(=N2)N([H])C(C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H])=O
Purity	On request
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

WNT-associated cardiomyogenesis · Literature evidence

Biological Activity

KY02111 is a small molecule for cardiomyocyte differentiation research in human pluripotent stem cells. KY02111 promoted differentiation toward cardiomyocytes following a cell-based compound screen.

In Vitro

Endpoint	Model / conditions / source	Reported result
Differentiation phenotype	Human embryonic and induced pluripotent stem cells. [1]	KY02111 promoted differentiation toward cardiomyocytes following a cell-based compound screen.
Signaling mechanism	WNT pathway analyses in human pluripotent stem cells. [1]	Results supported WNT inhibition through a mode distinct from previously studied WNT inhibitors; a direct molecular target was not established.
Combination context	KY02111 with additional WNT-signaling modulators. [1]	Robust cardiac differentiation was obtained in defined, xeno-free medium without serum, BMP4, Activin A or insulin. The combination result is not a KY02111-only efficacy estimate.

In Vivo

No compound-specific animal efficacy result is established by the sources summarized here.

Compound and Evidence Context

Endpoint	Model / conditions / source	Reported result
Protocol coverage	Primary publication abstract. [1]	A complete concentration and treatment-day schedule has not been verified for this page; no numerical cardiomyocyte yield is assigned.